7th Tumor Models Immuno Oncology 2024

With 2023 on track to see further growth in the immuno-oncology field, the availability of tools that offers drug developers and researchers advantages that weren't available to them even a few years ago is increasing rapidly. Despite this growth over the last 12 months, the IO community still faces critical challenges in translating drugs to the clinic. The IO community must continue to work together to overcome critical bottlenecks around immunomodulating agent utilization, dosing and efficacy as well as looking for predictive biomarkers to boost our clinical and therapeutic index confidence.

Next January, the 7th annual Tumor Models for Immuno-Oncology Summit returns in person to San Francisco, and remains the definitive meeting focusing on disease modelling to empower you to:

- Discover how you can improve your in vivo preclinical toolbox to usher in the next-generation of transgenic mouse models, to advance therapies to the clinic faster
- Discuss combination therapy challenges including dosing, tumor heterogeneity, target engagement, and resistance
- Deep dive into specific cell types and how therapeutics utilizing these cells can be accurately modelled
- Meet and network with selected CROs, model developers and academics to hear their latest platforms and form meaningful partnerships

We are excited about the return of a face-to-face meeting where we can reconnect with the community. Tailored with industry IO model experts including Amgen, Umoja Therapeutics, IGM Biosciences, Crown, JAX , this 3-days summit will guide and prepare you for the next gen IO development, increasing your clinical relevancy and speed-to-clinic!

URLs:
Website: https://go.evvnt.com/1422060-0?pid=10018
Tickets: https://go.evvnt.com/1422060-2?pid=10018
Brochure: https://go.evvnt.com/1422060-3?pid=10018

Price:
Free: USD 0.00

Speakers: Ana Krtolica, Senior Vice President Preclinical Development, Oryn Therapeutics, Anupurna Kaul, Senior Associate Scientist, Amgen Inc., Dayson Moreira, Senior Scientist, Sutro Biopharma, Deepali Sawant, Principal Scientist, Amgen Inc., Dirk Brockstedt, Chief Scientific Officer, RAPT Therapeutics, Elsa Quintana, Senior Director, Revolution Medicines, Javier Pineda, Bioinformatics Lead, Scientist, Joshua Breunig, Associate Professor, Cedars-Sinai Medical Center, Kader Thiam, Senior VP Discovery and Preclinical Models, GenOway, Katie Grausam, Postdoctoral Scientist, Cedars-Sinai Medical Center, Kelly Lee, Associated Director, In Vivo Team Lead, Senti Biosciences Inc., Liqin Liu, Senior Director, IGM Biosciences, Michael Brehm, Associate Professor, University of Massachusetts Medical School, Monika Buczek, Director of Business Development, Certis Oncology Solution, Poonam Yakkundi, Senior Scientist, IGM Biosciences, Shon Green, Senior Director - Translational Sciences, Umoja Biopharma, Stacey Xu, Senior Scientist - In Vivo Pharmacology, Research and Development, Triumvira Immunologics Inc, Stephanie Casey, Parks Senior Scientist, Amgen Inc., Susana Hernandez, Scientist, Umoja Biopharma, Tahmineh Safaie, Senior Associate Scientist, Nammi Therapeutics Inc, Tessa DesRochers, Chief Scientific Officer, Kiyatec Inc, Yufei Wang, Medicine and Research Fellow, Dana-Farber Cancer Institute, Zhenya Koliesnik, Senior Scientist, Synthekine Inc.